Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of BioCentury, Week in Review: Clinical Results

BioCentury, Week in Review Current Issue
  • Autologous dermal sheath cup cells: Phase I/II data

    RepliCel Life Sciences Inc. (OTCBB:REPCF), Vancouver, B.C. Product: Autologous dermal sheath cup cells (DSCC) Business: Dermatology Molecular target: NA Description: Dermal sheath cup cells (DSCC) isolated from a …

    Published on 5/21/2012
  • Blinatumomab: Phase II data

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Product: Blinatumomab (AMG 103) (formerly MT103) Business: Cancer Molecular target: CD19 Description: Bispecific T cell engager (BiTE) against CD19 Indication: Treat acute…

    Published on 5/21/2012
  • Cabozantinib: Additional Phase III data

    Exelixis Inc. (NASDAQ:EXEL), South San Francisco, Calif. Product: Cabozantinib (XL184) Business: Cancer Molecular target: Vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) (VEGFR-2); c-Met receptor …

    Published on 5/21/2012
  • Diltiazem cream: Phase III data

    S.L.A. Pharma AG, Liestal, Switzerland Ventrus Biosciences Inc. (NASDAQ:VTUS), New York, N.Y. Product: Diltiazem cream (VEN 307) Business: Gastrointestinal Molecular target: NA Description: Topical formulation of …

    Published on 5/21/2012
  • EP-101: Phase IIb data

    Elevation Pharmaceuticals Inc., San Diego, Calif. Product: EP-101 Business: Pulmonary Molecular target: Muscarinic receptor Description: Inhaled formulation of glycopyrrolate, a long-acting muscarinic antagonist (LAMA) …

    Published on 5/21/2012
  • Erbitux cetuximab: Phase III data

    Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Merck KGaA (Xetra:MRK), Darmstadt, Germany Product: Erbitux cetuximab Business: Cancer Molecular target: Epidermal …

    Published on 5/21/2012
  • External Trigeminal Nerve Stimulation: Phase Ib data

    NeuroSigma Inc., Los Angeles, Calif. Product: External Trigeminal Nerve Stimulation (eTNS) Business: Neurology Molecular target: NA Description: Trigeminal nerve stimulation system utilizing external electrodes and a …

    Published on 5/21/2012
  • FluGEM: Phase I data

    Mucosis B.V., Groningen, the Netherlands Product: FluGEM Business: Infectious Molecular target: NA Description: Mucosal-based influenza vaccine using Mimopath technology containing bacterium-like particles (BLPs) and …

    Published on 5/21/2012
  • GAL-021: Phase I data

    Galleon Pharmaceuticals Inc., Newtown, Pa. Product: GAL-021 Business: Pulmonary Molecular target: NA Description: Undisclosed small molecule designed to support respiratory drive in surgical and critical care patients …

    Published on 5/21/2012
  • GFT505: Phase I data

    Genfit S.A. (Euronext:ALGFT), Lille, France Product: GFT505 Business: Hepatic Molecular target: Peroxisome proliferation activated receptor (PPAR) Description: Dual peroxisome proliferation activated receptor (PPAR) …

    Published on 5/21/2012
  • HPV assay diagnostic data

    Trovagene Inc. (Pink:TROV), San Diego, Calif. Product: HPV assay Business: Diagnostic Molecular target: NA Description: Urine-based HPV detection assay Indication: Detect high-risk HPV subtypes from urine specimens …

    Published on 5/21/2012
  • Human anti-M2e antibody: Phase I data

    Theraclone Sciences Inc., Seattle, Wash. Zenyaku Kogyo Co. Ltd., Tokyo, Japan Product: Human anti-M2e antibody (TCN-032) Business: Infectious Molecular target: Influenza A virus matrix protein M2 (M2) Description: Human…

    Published on 5/21/2012
  • IMO-2055: Phase Ib data

    Idera Pharmaceuticals Inc. (NASDAQ:IDRA), Cambridge, Mass. Product: IMO-2055, EMD 1201081 Business: Cancer Molecular target: Toll-like receptor 9 (TLR9) Description: Second-generation synthetic immune modulatory …

    Published on 5/21/2012
  • Intranasal naloxone: Preliminary Phase II data

    Lightlake Therapeutics Inc. (OTCBB:LLTP), London, U.K. Product: Intranasal naloxone Business: Neurology Molecular target: NA Description: Opioid antagonist nasal spray Indication: Treat binge eating disorder Endpoint: …

    Published on 5/21/2012
  • Lu AA21004: Phase III data

    H. Lundbeck A/S (CSE:LUN), Copenhagen, Denmark Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Lu AA21004 Business: Neurology Molecular target: Serotonin (5-HT3) receptor; Serotonin (5-HT1A) receptor …

    Published on 5/21/2012
  • Lu AA21004: Phase III data

    H. Lundbeck A/S (CSE:LUN), Copenhagen, Denmark Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Lu AA21004 Business: Neurology Molecular target: Serotonin (5-HT3) receptor; Serotonin (5-HT1A) receptor …

    Published on 5/21/2012
  • Lu AA21004: Phase III data

    H. Lundbeck A/S (CSE:LUN), Copenhagen, Denmark Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Lu AA21004 Business: Neurology Molecular target: Serotonin (5-HT3) receptor; Serotonin (5-HT1A) receptor …

    Published on 5/21/2012
  • Matrix M adjuvant: Phase I data

    Isconova AB (SSE:ISCO), Uppsala, Sweden Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Matrix M adjuvant Business: Infectious Molecular target: NA Description: Vaccine adjuvant Indication: Prevent seasonal …

    Published on 5/21/2012
  • MDT-637: Phase I data

    Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. MicroDose Therapeutx Inc., Monmouth Junction, N.J. Product: MDT-637 Business: Infectious Molecular target: NA Description: Inhalable small molecule antiviral …

    Published on 5/21/2012
  • MDT-637: Phase I data

    Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. MicroDose Therapeutx Inc., Monmouth Junction, N.J. Product: MDT-637 Business: Infectious Molecular target: NA Description: Inhalable small molecule antiviral …

    Published on 5/21/2012
  • MEK162: Phase II data

    Array BioPharma Inc. (NASDAQ:ARRY), Boulder, Colo. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: MEK162 (formerly ARRY-162) Business: Cancer Molecular target: MEK Description: Oral MEK inhibitor …

    Published on 5/21/2012
  • MGN1703: Interim Phase II data

    Mologen AG (Xetra:MGN), Berlin, Germany Product: MGN1703 Business: Cancer Molecular target: Toll-like receptor 9 (TLR9) Description: Toll-like receptor 9 (TLR9) agonist based on double Stem Loop Immunomodulator (dSLIM) …

    Published on 5/21/2012
  • Midaform Insulin PharmFilm: Phase I data

    Midatech Ltd., Abingdon, U.K. MonoSol Rx LLC, Warren, N.J. Product: Midaform Insulin PharmFilm, Transbuccal Insulin PharmaFilm Business: Endocrine/Metabolic Molecular target: NA Description: Oral film formulation of …

    Published on 5/21/2012
  • Nalcol naloxone: Phase II data

    S.L.A. Pharma AG, Liestal, Switzerland Product: Nalcol naloxone Business: Gastrointestinal Molecular target: NA Description: Slow-release, oral formulation of naloxone Indication: Treat opioid-induced constipation (OIC)…

    Published on 5/21/2012
  • ONO-4538: Phase Ib data

    Ono Pharmaceutical Co. Ltd. (Tokyo:4528; Osaka:4528), Osaka, Japan Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: ONO-4538, MDX-1106, BMS-936558 Business: Cancer Molecular target: PD-1 receptor (PDCD1) (PD…

    Published on 5/21/2012

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993

Log In


Forgot password  |  Forgot Login


If you are a subscriber, but have forgotten or have never received a password, please go here and ask us to send you a new one.

Catalent

Week in Review

The biotech industry's most complete compendium of corporate, clinical and financial transactions provides an efficient surveillance system for:

  • Deals
  • Regulatory Events
  • Clinical Results
  • Financings
  • Management News

Need custom ComputerVision Software?